Investing.com - Cue Biopharma (NASDAQ: CUE) reported second quarter EPS of $-0.090, $0.05 better than the analyst estimate of $-0.140. Revenue for the quarter came in at $2.95M versus the consensus estimate of $1.6M.
Cue Biopharma’s stock price closed at $0.79. It is up 8.980% in the last 3 months and up 24.610% in the last 12 months.
Cue Biopharma saw 1 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Cue Biopharma’s stock price’s past reactions to earnings here.
According to InvestingPro, Cue Biopharma’s Financial Health score is "fair performance".
Check out Cue Biopharma’s recent earnings performance, and Cue Biopharma’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
Cue Biopharma earnings beat by $0.05, revenue topped estimates
Published 2 months ago
Aug 12, 2025 at 10:04 PM
Positive
Auto